BNR (Burning Rock Biotech) Current Deferred Revenue: $16.70 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BNR Burning Rock Biotech Ltd BNR
59 GF Score
Price $8.91
GF Value $7.46
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Burning Rock Biotech Current Deferred Revenue?

Burning Rock Biotech BNR -3.10% 59 Current Deferred Revenue is $16.70 Mil as of Mar. 2026. GuruFocus rates BNR with a GF Score™ of 59/100 and a GF Value™ of $7.46 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Burning Rock Biotech's current deferred revenue for the quarter that ended in Mar. 2026 was $16.70 Mil.

Burning Rock Biotech Current Deferred Revenue Related Terms

Burning Rock Biotech Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Burning Rock Biotech's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Burning Rock Biotech Current Deferred Revenue Chart

Burning Rock Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only 22.58 21.44 18.45 16.27 15.39

Burning Rock Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.25 14.40 15.03 15.39 16.70
BNR
59GF Score
Burning Rock Biotech Ltd BNR
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $16.70 Mil mean?
Burning Rock Biotech (BNR) has a Current Deferred Revenue of $16.70 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Burning Rock Biotech and its competitors.
Is Burning Rock Biotech's Current Deferred Revenue too high?
Burning Rock Biotech's current Current Deferred Revenue is $16.70 Mil. Overall, Burning Rock Biotech has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's Current Deferred Revenue compare to XGN and PRPO?
Burning Rock Biotech's Current Deferred Revenue of $16.70 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Diagnostics & Research company?
A good Current Deferred Revenue depends on the Medical Diagnostics & Research industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Burning Rock Biotech and its competitors. Burning Rock Biotech's current Current Deferred Revenue is $16.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (BNR) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.46, compared to a current price of $8.91 — trading 19.4% above its estimated fair value. The current Current Deferred Revenue is $16.70 Mil. Burning Rock Biotech's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Burning Rock Biotech (BNR), the current Current Deferred Revenue is $16.70 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Burning Rock Biotech (BNR) Overvalued in 2026?

Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued. The current stock price of $8.91 is trading 19.4% above its estimated GF Value™ of $7.46. GuruFocus considers Burning Rock Biotech to be Modestly Overvalued.

Key valuation signals for BNR:

  • Current Deferred Revenue: $16.70 Mil
  • GF Value™: $7.46 vs. price of $8.91 (19.4% above fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the BNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Burning Rock Biotech Business Description

Other Exchanges 6BU0:Germany
Address No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
59GF Score

Get the complete analysis for BNR

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.91
Price
$7.46
GF Value